Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board.

Literature DB >> 30609967

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board.

Maria Cristina Mingari¹, Gabriella Pietra², Lorenzo Moretta³.

Abstract

Antibodies directed towards checkpoint inhibitors have unveiled extraordinary potential in cancer therapy. An article by the Vivier group (Cell 2018;175:1731-1743) shows that blocking the HLA-E-specific NKG2A inhibitory receptor, expressed by NK and inducible in T cells, results in benefits against poor prognosis tumors. Moreover, NKG2A and PD-1/PD-L1 mAb combinations unleash tumor-specific T cell proliferation and memory.

Entities: Disease Gene

Mesh：

Substances：
Immunologic Factors

Year: 2019 PMID： 30609967 DOI： 10.1016/j.it.2018.12.009

Source DB: PubMed Journal: Trends Immunol ISSN： 1471-4906 Impact factor: 16.687

Keyword Cloud
Cited

17 in total

1. Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules.

Authors: Chiara Barberi; Claudia De Pasquale; Alessandro Allegra; Giacomo Sidoti Migliore; Daniela Oliveri; Fabrizio Loiacono; Vanessa Innao; Caterina Musolino; Daniela Pende; Claudia Cantoni; Paolo Carrega; Maria Cristina Mingari; Stefania Campana; Guido Ferlazzo
Journal: Blood Adv Date: 2020-05-26

Review 2. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.

Authors: Daniela Pende; Michela Falco; Massimo Vitale; Claudia Cantoni; Chiara Vitale; Enrico Munari; Alice Bertaina; Francesca Moretta; Genny Del Zotto; Gabriella Pietra; Maria Cristina Mingari; Franco Locatelli; Lorenzo Moretta
Journal: Front Immunol Date: 2019-05-28 Impact factor: 7.561

Review 3. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.

Authors: Francesca Romana Mariotti; Linda Quatrini; Enrico Munari; Paola Vacca; Lorenzo Moretta
Journal: Front Immunol Date: 2019-04-26 Impact factor: 7.561

Review 4. Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).

Authors: Michela Falco; Daniela Pende; Enrico Munari; Paola Vacca; Maria C Mingari; Lorenzo Moretta
Journal: HLA Date: 2019-04 Impact factor: 4.513

5. T1D progression is associated with loss of CD3⁺CD56⁺ regulatory T cells that control CD8⁺ T cell effector functions.

Authors: Giuseppe Terrazzano; Sara Bruzzaniti; Valentina Rubino; Marianna Santopaolo; Anna Teresa Palatucci; Angela Giovazzino; Claudia La Rocca; Paola de Candia; Annibale Puca; Francesco Perna; Claudio Procaccini; Veronica De Rosa; Chiara Porcellini; Salvatore De Simone; Valentina Fattorusso; Antonio Porcellini; Enza Mozzillo; Riccardo Troncone; Adriana Franzese; Johnny Ludvigsson; Giuseppe Matarese; Giuseppina Ruggiero; Mario Galgani
Journal: Nat Metab Date: 2020-02-17

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board.

1. Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules.

Review 2. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.

Review 3. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.

Review 4. Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).

5. T1D progression is associated with loss of CD3⁺CD56⁺ regulatory T cells that control CD8⁺ T cell effector functions.

Review 6. Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle.

Review 7. Exploiting Human NK Cells in Tumor Therapy.

Review 8. Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28.

Review 9. Targeting Natural Killer Cells for Tumor Immunotherapy.

Review 10. Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board.

1. Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules.

Review 2. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.

Review 3. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.

Review 4. Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).

5. T1D progression is associated with loss of CD3+CD56+ regulatory T cells that control CD8+ T cell effector functions.

Review 6. Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle.

Review 7. Exploiting Human NK Cells in Tumor Therapy.

Review 8. Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28.

Review 9. Targeting Natural Killer Cells for Tumor Immunotherapy.

Review 10. Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?

5. T1D progression is associated with loss of CD3⁺CD56⁺ regulatory T cells that control CD8⁺ T cell effector functions.